Institute Krems Bioanalytics
The Institute Krems Bioanalytics is contract research institute of IMC Krems.
The Institute Krems Bioanalytics provides contract research for the pharmaceutical industry, biotech companies and academic institutions since 2014. It is a part of the Biotech Area Krems, which includes three universities and several biotech companies.
The research groups at the institute have in-depth scientific expertise in haematology, immunology and oncology. The research focus is primarily on cutting-edge bioanalytical services for large molecules and vaccine development.
The institute offers a wide range of advanced bioanalytical services and develops tailored analytical solutions for specific drug or vaccine development programmes.
It has a long-standing expertise in the development and validation of customised and GxP-compliant analytical assays for the assessment of immunogenicity, drug stability, pharmacokinetics and enzyme kinetics.
In addition, the Institute Krems Bioanalytics develops complex cell-based assays for drug efficacy testing or biopotency characterisation for lot releases. It offers sample analytics for early or late preclinical studies (R&D or GLP, Good Laboratory Practice) or for clinical trials (GCP, Good Clinical Practice). Since its foundation, the institute has participated in more than 20 clinical and 120 preclinical studies.
The institute's mission is to operate as one-stop bioanalytical service provider, develop cutting-edge and GxP compliant technologies for sample analytics, create reliable scientific data, operate under full regulatory compliance and establish strategic partnerships in innovative research areas.
Selected technologies
- Enzyme linked immunosorbent assays (ELISA)
- Electrochemiluminescence (ECL)
- Luminex multiplex assays
- Enzyme activity assays
- Blood coagulation assays
- Flow cytometry
- Cell-based assays
- Organotypic disease modelling
- Starting September 2021: Mass Spectrometry
" Krems Bioanalytics specialises in innovative bioanalytical solutions for biotherapeutics and vaccines with strong expertise in immunogenicity assessment, including customised method development, GxP-compliant assay validation and sample analytics for preclinical research and clinical trials. "
Andreas Eger, Head of Institute Krems Bioanalytics
Team
Get to know the core team of our Institute Krems Bioanalytics.
Bioanalytics
![]()
![Mag. Dr. Peter Allacher | Head of Operations / Institute Krems Bioanalytics - IMC Fachhochschule Krems]()
Mag. Dr. Peter Allacher
Head of Operations / Institute Krems Bioanalytics
Bioanalytics
- Medical and Pharmaceutical BiotechnologyBachelor of Science in Engineering / full-time
Schweiger, H., Rejtö, J., Hofbauer, C.J., Berg, V., Allacher, P., Zwiauer, K., Feistritzer, C., Schuster, G., Ay, C., Reipert, B.M., Pabinger, I. (2022): Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Advances, 6(3): 946-958.
Doi: https://doi.org/10.1182/bloodadvances.2021005745Lubich, C., Allacher, P., de la Rosa, M., Bauer, A., Prenninger, T., Horling, F. M., Siekmann, J., Oldenburg, J., Scheiflinger, F., & Reipert, B. M. (2016): The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?. Pharmaceutical research, 33(9): 2239-49.
Doi: https://doi.org/10.1007/s11095-016-1961-xJaki, T., Allacher, P., & Horling, F. (2016): A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?. Journal of pharmaceutical and biomedical analysis, 128: 166-73.
Doi: https://doi.org/10.1016/j.jpba.2016.05.031Hofbauer, C.J., Whelan,S.F.J., Hirschler, M., Allacher, P., Horling, F.M., Lawo, J.-P., Oldenburg, J., Tiede, A., Male, C., Windyga, J., Greinacher, A., Knöbl, P.N., Schrenk, G., Koehn, J., Scheiflinger, F., Reipert, B.M. (2015): Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood, 125(7): 1180-1188.
Doi: https://doi.org/10.1182/blood-2014-09-598268Jaki, T., Lawo, J.-P., Wolfsegger, M.J., Allacher, P., Horling, F. (2014): A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. Journal of pharmaceutical and biomedical analysis, 88: 27-35.
Doi: https://doi.org/10.1016/j.jpba.2013.08.013Whelan, S. F., Hofbauer, C. J., Horling, F. M., Allacher, P., Wolfsegger, M. J., Oldenburg, J., Male, C., Windyga, J., Tiede, A., Schwarz, H. P., Scheiflinger, F., & Reipert, B. M. (2013): Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood, 121(6): 1039-1048.
Doi: https://doi.org/10.1182/blood-2012-07-444877Pordes, A. G., Baumgartner, C. K., Allacher, P., Ahmad, R. U., Weiller, M., Schiviz, A. N., Schwarz, H. P., & Reipert, B. M. (2011): T cell-independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist. Blood, 118(11): 3154–3162.
Doi: https://doi.org/10.1182/blood-2011-02-336198Jaki, T., Lawo, J.-P., Wolfsegger, M.J., Singer, J., Allacher, P., Horling, F. (2011): A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. Journal of pharmaceutical and biomedical analysis, 55(5): 1148-1156.
Doi: https://doi.org/10.1016/j.jpba.2011.04.006Allacher, P., Baumgartner, C. K., Pordes, A. G., Ahmad, R. U., Schwarz, H. P., & Reipert, B. M. (2011): Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9. Blood, 117(1): 259-267.
Doi: https://doi.org/10.1182/blood-2010-06-289009Reipert, B. M., Allacher, P., Hausl, C., Pordes, A. G., Ahmad, R. U., Lang, I., Ilas, J., Windyga, J., Klukowska, A., Muchitsch, E. M., & Schwarz, H. P. (2010): Modulation of factor VIII-specific memory B cells. Haemophilia, 16(102): 25-34.
Doi: https://doi.org/10.1111/j.1365-2516.2008.01962.x
Mag. Dr. Peter AllacherHead of Operations / Institute Krems Bioanalytics
Institute Krems Bioanalytics
![]()
Dr. Christian Lubich
Head of Institute / Institute Krems Bioanalytics
Institute Krems Bioanalytics
- Immunology
- Flow Cytometry
- Bioanalytical method development
Lubich, C., Steinitz, KN., Hoelbl, B., Prenninger, T., van Helden, PM., Weiller, M., Reipert, BM. (2022): Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells. Frontiers in Immunology.
Doi: https://doi.org/10.3389/fimmu.2022.975680Carestia, A., Kim, S. J., Horling, F., Rottensteiner, H., Lubich, C., Reipert, B. M., Crowe, B. A., & Jenne, C. N. (2021): Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector. Molecular therapy. Methods & clinical development, 20(95-108).
Doi: https://doi.org/10.1016/j.omtm.2020.10.023Anzengruber, J., Lubich, C., Prenninger, T., Gringeri, A., Scheiflinger, F., Reipert, B. M., & Malisauskas, M. (2018): Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles. Journal of thrombosis and haemostasis : JTH, 16(6): 1176–1181.
Doi: https://doi.org/10.1111/jth.14125
Dr. Christian LubichHead of Institute / Institute Krems Bioanalytics![]()
![Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger | Deputy Head of Institute / Institute Krems Bioanalytics - IMC Fachhochschule Krems]()
Prof.(FH) Priv. Doz. Mag. Dr. Andreas Eger
Deputy Head of Institute / Institute Krems Bioanalytics
Institute Krems Bioanalytics
- Drug Discovery
- Organotypic Disease Models
- Bioanalytics and Biomarker
- Medical and Pharmaceutical BiotechnologyMaster of Science in Engineering / full-time
-
Stoffwechsel-Plasma-Analyse bei metabolischem Syndrom und Tumorkachexie
Project Leader, Department of Science & Technology
-
DNA Methylierung im Lungenkrebs und ihre geschlechtsspezifische
Auswirkung auf die Effizienz epigenetischer Therapien
Department of Science & Technology
-
Entwicklung von therapeutischen Peptiden für Krebs- und regenerative Medizin
Project Leader, Department of Science & Technology
-
Etablierung der molekularen Toxikologie für rasche, frühzeitige sowie sensitive Toxizitätsbestimmungen und Biokompatibilität
Department of Science & Technology
-
Entwicklung komplexer extrakorporaler Karzinommodelle für die Identifikation personalisierter Krebstherapien
Project Leader, Department of Science & Technology
-
AdsorbTech: Entwicklung einer neuen Technologieplattform für Peptid-basierte therapeutische Apheresesysteme
Department of Science & Technology
-
Entwicklung neuer immunregulierender Peptide und geschlechtsspezifischer organotypischer Zellmodelle für humane Sepsis
Department of Science & Technology
-
Entwicklung neuer Methoden zur Verbesserung von immuntherapeutischen Verfahren in der Onkologie
Project Leader, Department of Science & Technology
-
Funktionale Validierung prädiktiver Biomarker für zielgerichtete Krebstherapien
Project Leader, Department of Science & Technology
-
Etablierung innovativer humaner Tumor-Mimetika für das Screening von bioaktiven Wirkstoffen
Project Leader, Department of Science & Technology
Hundsberger, H., Stierschneider, A., Sarne, V., Ripper, D., Schimon, J., Weitzenböck, H. P., Schild, D., Jacobi, N., Eger, A., Atzler, J., Klein, C. T., & Wiesner, C. (2021): Concentration-Dependent Pro- and Antitumor Activities of Quercetin in Human Melanoma Spheroids: Comparative Analysis of 2D and 3D Cell Culture Models. Molecules (Basel, Switzerland), 26(3): 717.
Doi: https://doi.org/10.3390/molecules26030717Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., Önder, K., Hundsberger, H., Wiesner, C., & Eger, A. (2017): Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling. Oncotarget, 8(64): 107423–107440.
Doi: https://doi.org/10.18632/oncotarget.22475Jacobi, N., Smolinska, V., Seeboeck, R., Stierschneider, A., Klein, C., Hofmann, E., Wiesner, C., Mohr, T., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2017): 3D Anti-Cancer drug discovery models: A promising approach for precision medicine. In IMC Fachhochschule Krems GmbH (Hrsg.), Online-Tagungsband FHK Forschungsforum 2017. Krems: FFH.
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017): ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 9(4): 33.
Doi: https://doi.org/10.3390/cancers9040033Hundsberger, H., Koppensteiner, A., Hofmann, E., Ripper, D., Pflüger, M., Stadlmann, V., Klein, C. T., Kreiseder, B., Katzlinger, M., Eger, A., Forster, F., Missbichler, A., & Wiesner, C. (2017): A Screening Approach for Identifying Gliadin Neutralizing Antibodies on Epithelial Intestinal Caco-2 Cells. SLAS discovery : advancing life sciences R & D, 22(8): 1035–1043.
Doi: https://doi.org/10.1177/2472555217697435Hofmann, E., Seeboeck, R., Jacobi, N., Obrist, P., Huter, S., Klein, C., Oender, K., Wiesner, C., Hundsberger, H., & Eger, A. (2016): The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker research, 7(4): 8.
Doi: https://doi.org/10.1186/s40364-016-0062-7Jacobi, N., Smolinska, V., Stierschneider, A., Klein, C., Oender, K., Lechner, P., Kaiser, H., Hundsberger, H., Eger, A. (2016): Development of organotypic cancer models for the identification of individualized cancer therapies. In FH des BFI Wien (Hrsg.), Online-Tagungsband FHK Forschungsforum 2016. Wien: FFH.
Herzog, J., Rid, R., Wagner, M., Hundsberger, H., Eger, A., Bauer, J., & Önder, K. (2015): Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways. BMC research notes, 8: 785.
Doi: https://doi.org/10.1186/s13104-015-1783-7Kreiseder, B., Holper-Schichl, Y. M., Muellauer, B., Jacobi, N., Pretsch, A., Schmid, J. A., de Martin, R., Hundsberger, H., Eger, A., & Wiesner, C. (2015): Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PloS one, 10(3): e0119402.
Doi: https://doi.org/10.1371/journal.pone.0119402Bakiri, L., Macho-Maschler, S., Custic, I., Niemiec, J., Guío-Carrión, A., Hasenfuss, S. C., Eger, A., Müller, M., Beug, H., & Wagner, E. F. (2015): Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression. Cell death and differentiation, 22(2): 336–350.
Doi: https://doi.org/10.1038/cdd.2014.157Spilka, R., Ernst, C., Bergler, H., Rainer, J., Flechsig, S., Vogetseder, A., Lederer, E., Benesch, M., Brunner, A., Geley, S., Eger, A., Bachmann, F., Doppler, W., Obrist, P., & Haybaeck, J. (2014): eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cellular oncology (Dordrecht), 37(4): 253–267.
Doi: https://doi.org/10.1007/s13402-014-0181-9Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P., & Wiesner, C. (2014): Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PloS one, 9(6): e97929.
Doi: https://doi.org/10.1371/journal.pone.0097929Kapuścik, A., Hrouzek, P., Kuzma, M., Bártová, S., Novák, P., Jokela, J., Pflüger, M., Eger, A., Hundsberger, H., Kopecký, J. (2013): Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent. Chembiochem : a European journal of chemical biology, 14(17): 2329-2337.
Doi: https://doi.org/10.1002/cbic.201300246Rid, R., Herzog, J., Maier, R. H., Hundsberger, H., Eger, A., Hintner, H., Bauer, J. W., Onder, K. (2013): Real-time monitoring of relative peptide-protein interaction strengths in the yeast two-hybrid system. Assay and drug development technologies, 11(4): 269-275.
Doi: https://doi.org/10.1089/adt.2012.496Pflüger, M., Kapuscik, A., Lucas, R., Koppensteiner, A., Katzlinger, M., Jokela, J., Eger, A., Jacobi, N., Wiesner, C., Hofmann, E., Onder, K., Kopecky, J., Schütt, W., Hundsberger, H. (2013): A combined impedance and AlphaLISA-based approach to identify anti-inflammatory and barrier-protective compounds in human endothelium. Journal of biomolecular screening, 18(1): 67-74.
Doi: https://doi.org/10.1177/1087057112458316Imhof, M., Karas, I., Gomez, I., Eger, A., & Imhof, M. (2013): Interaction of tumor cells with the immune system: implications for dendritic cell therapy and cancer progression. Drug discovery today, 18(1-2): 35-42.
Doi: https://doi.org/10.1016/j.drudis.2012.07.010Maier, C., Maier, R., Rid, R., Trost, A., Hundsberger, H., Eger, A., Hintner, H., Bauer, J., Onder, K. (2012): PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1,25-(OH)2D3 signaling. BMC molecular biology, 13: 18.
Doi: https://doi.org/10.1186/1471-2199-13-18Vonach, C., Viola, K., Giessrigl, B., Huttary, N., Raab, I., Kalt, R., Krieger, S., Vo, T. P., Madlener, S., Bauer, S., Marian, B., Hämmerle, M., Kretschy, N., Teichmann, M., Hantusch, B., Stary, S., Unger, C., Seelinger, M., Eger, A., Mader, R., Jäger, W., Schmidt, W., Grusch, M., Dolznig, H., Mikulits, W., Krupitza, G. (2011): NF-κB mediates the 12(S)-HETE-induced endothelial to mesenchymal transition of lymphendothelial cells during the intravasation of breast carcinoma cells. British journal of cancer, 105(2): 263-271.
Doi: https://doi.org/10.1038/bjc.2011.194Amatschek, S., Lucas, R., Eger, A., Pflueger, M., Hundsberger, H., Knoll, C., Grosse-Kracht, S., Schuett, W., Koszik, F., Maurer, D., Wiesner, C. (2011): CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. British journal of cancer, 104(3): 469-479.
Doi: https://doi.org/10.1038/sj.bjc.6606056Spaderna, S., Schmalhofer, O., Wahlbuhl, M., Dimmler, A., Bauer, K., Sultan, A., Hlubek, F., Jung, A., Strand, D., Eger, A., Kirchner, T., Behrens, J., & Brabletz, T. (2008): The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer research, 68(2): 537–544.
Doi: https://doi.org/10.1158/0008-5472.CAN-07-5682Mikula M., Lahsnig C., Fischer A. N. M., Proell V., Huber H, Fuchs E., Eger A., Beug H. and Mikulits W. (2007): Epithelial plasticity of hepatocytes during liver tumor progression. Stem cells and their potential for clinical application. NATO Science for Peace and Security. Series/NATO Science Foundation. Springer Netherland, Edition 1.
Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., Brabletz, T., Strand, D., Obrist, P., Sommergruber, W., Schweifer, N., Wernitznig, A., Beug, H., Foisner, R., & Eger, A. (2007): The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene, 26(49): 6979–6988.
Doi: https://doi.org/10.1038/sj.onc.1210508Aigner, K., Descovich, L., Mikula, M., Sultan, A., Dampier, B., Bonné, S., van Roy, F., Mikulits, W., Schreiber, M., Brabletz, T., Sommergruber, W., Schweifer, N., Wernitznig, A., Beug, H., Foisner, R., & Eger, A. (2007): The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS letters, 581(8): 1617-24.
Doi: https://doi.org/10.1016/j.febslet.2007.03.026Pacher, M., Seewald, M. J., Mikula, M., Oehler, S., Mogg, M., Vinatzer, U., Eger, A., Schweifer, N., Varecka, R., Sommergruber, W., Mikulits, W., & Schreiber, M. (2007): Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis, 28(1): 49-59.
Doi: https://doi.org/10.1093/carcin/bgl091Spaderna, S., Schmalhofer, O., Hlubek, F., Berx, G., Eger, A., Merkel, S., Jung, A., Kirchner, T., & Brabletz, T. (2006): A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology, 131(3): 830–840.
Doi: https://doi.org/10.1053/j.gastro.2006.06.016Stary, M., Pasteiner, W., Summer, A., Hrdina, A., Eger, A., & Weitzer, G. (2005): Parietal endoderm secreted SPARC promotes early cardiomyogenesis in vitro. Experimental cell research, 310(2): 331-43.
Doi: https://doi.org/10.1016/j.yexcr.2005.07.013Eger, A., Mikulits, W. (2005): Models of Epithelial to Mesenchymal Transition. Drug Discovery Today: Disease Models, 2(1): 57-63.
Doi: https://doi.org/10.1016/j.ddmod.2005.04.001Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005): DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene, 24(14): 2375-85.
Doi: https://doi.org/10.1038/sj.onc.1208429Eger, A., Stockinger, A., Park, J., Langkopf, E., Mikula, M., Gotzmann, J., Mikulits, W., Beug, H., & Foisner, R. (2004): β-catenin and TGFβ signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene, 23(15): 2672-2680.
Doi: https://doi.org/10.1038/sj.onc.1207416Gotzmann, J., Mikula, M., Eger, A., Schulte-Hermann, R., Foisner, R., Beug, H., & Mikulits, W. (2004): Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutation research, 566(1): 9–20.
Doi: https://doi.org/10.1016/s1383-5742(03)00033-4Stockinger, A., Eger, A., Wolf, J., Beug, H., & Foisner, R. (2001): E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. The Journal of cell biology, 154(6): 1185–1196.
Doi: https://doi.org/10.1083/jcb.200104036Eger A. and Foisner R. (2000): Dynamic and cross talk of junctional proteins: a molecular basis for the regulation of cell adhesion and epithelial polarity. Protoplasma, 211(3-4): 125-133.
Eger, A., Stockinger, A., Schaffhauser, B., Beug, H., & Foisner, R. (2000): Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. The Journal of cell biology, 148(1): 173-188.
Doi: https://doi.org/10.1083/jcb.148.1.173Gotzmann, J., Eger, A., Meissner, M., Grimm, R., Gerner, C., Sauermann, G., & Foisner, R. (1997): Two-dimensional electrophoresis reveals a nuclear matrix-associated nucleolin complex of basic isoelectric point. Electrophoresis, 18(14): 2645–2653.
Doi: https://doi.org/10.1002/elps.1150181421Eger, A., Stockinger, A., Wiche, G., & Foisner, R. (1997): Polarisation-dependent association of plectin with desmoplakin and the lateral submembrane skeleton in MDCK cells. Journal of cell science, 110: 1307-1316.
Prof.(FH) Priv. Doz. Mag. Dr. Andreas EgerDeputy Head of Institute / Institute Krems Bioanalytics
